Huntington’s Disease (HD) Chorea Resources | AUSTEDO XR ...
Find downloadable resources to help you support patients with HD chorea throughout treatment. View helpful videos about HD chorea and AUSTEDO XR. See Prescribing Information, including Boxed …
Huntington’s Disease Patient Resources for AUSTEDO XR®
HELPFUL RESOURCES Learn more about Huntington's disease (HD) chorea, patient support, and treatment with AUSTEDO XR® in these downloadable guides.
Austedo and Austedo XR (deutetrabenazine) for Huntington’s disease
Jun 3, 2024 · Austedo (deutetrabenazine) is an approved therapy, also available in an extended-release formulation, for chorea in Huntington's disease.
Study Explores Tardive Dyskinesia Outcomes With Deutetrabenazine Use
Nov 12, 2024 · Teva also presented findings on real-world patient experience with Austedo XR from a noninterventional, prospective, cross-sectional survey. The survey included adults with TD or …
Teva’s New Real-World Evidence Confirms Effectiveness and Patient ...
Apr 19, 2024 · Almost 80% of patients with Huntington's disease (HD) chorea were able to achieve optimal dosing within four weeks with the 4-week Titration Kit in final START study results START …
Austedo Patient Tips: 7 things you should know - Drugs.com
Oct 30, 2025 · 6. Response and effectiveness Huntington’s chorea is a rare, hereditary, and fatal disorder of nerve cells in the brain. The associated chorea results in involuntary, random, twisting, or …
Teva to Present New Data Supporting Safety, Efficacy and Real-World ...
Nov 2, 2023 · 92% of patients with Huntington's disease (HD) chorea achieved optimal dosing by week 12 with treatment on the AUSTEDO 4-week patient titration kit according to early results from the …
Austedo: Regaining Control Over Uncontrolled Movements in ... - WebMD
Jul 16, 2024 · Austedo (aw-STED-oh) was approved in 2017 and is the first medicine approved to treat both tardive dyskinesia and chorea caused by Huntington’s disease.
Reaction and Benefits of Deutetrabenazine One Pill, Once-Daily Tablet ...
Jun 15, 2024 · Deutetrabenazine (Austedo XR; Teva Pharmaceuticals), a vesicular monoamine transporter 2 (VMAT) inhibitor, was originally approved as a twice-daily treatment for chorea …
Huntington’s Disease (HD) Chorea | AUSTEDO XR® …
AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with …